一个随机临床试验的低剂量大麻提取物在阿尔茨海默氏症的疾病
Rafael de Morais Cury1, Taynara da Silva1, Fernando Cezar-Dos-Santos1
1Laboratório de Cannabis e Psicodélicos, School of Medicine, Universidade Federal da Integração Latino-Americana, Foz do Iguaçu, PR, Brazil.
Journal of Alzheimer's disease : JAD
|October 29, 2025
概括
低剂量THC-CBD大麻素提取物对阿尔茨海默病 (AD) 痴呆症症状显示出潜在的益处. 这个迄今为止最长的试验表明了安全有效的治疗选择,但需要进一步的研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 临床前和临床数据表明,低剂量的大麻素可以缓解阿尔茨海默病 (AD) 症状.
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是认知能力下降和痴呆.
- 目前阿尔茨海默病的治疗选择有限,需要探索新的治疗方法.
研究的目的:
- 评估一个平衡的THC-CBD大麻素提取物在患有AD相关痴呆症的患者的安全性和有效性.
- 评估每天口服THC-CBD提取物对认知功能和不良事件的影响.
- 确定大麻素作为治疗AD症状管理的治疗剂的潜力.
主要方法:
- 第二阶段,随机,双盲,安慰剂控制的临床试验.
- 纳入标准:60至80岁的患者,被诊断患有AD相关痴呆症.
- 干预:每天口服安慰剂或THC-CBD提取物 (0.350mgTHC,0.245mgCBD) 26周.
主要成果:
- 与安慰剂相比,THC-CBD组的迷你精神状态检查 (MMSE) 总分在26周后显著改善.
- 两组之间的二次结果或不良事件发生率没有显著差异.
- 这项研究是迄今为止评估大麻素对阿兹海默症患者影响的最长的临床试验.
结论:
- 低剂量THC-CBD提取物显示出作为AD相关痴呆症的安全有效治疗选择的潜力.
- 这项研究提供了初步证据,支持使用大麻素来管理AD症状.
- 需要进行更大,更长期的临床试验来证实这些发现,并确定AD痴呆症的大麻素治疗方法.
相关概念视频
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
665
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
665